Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). The OPDP issued a warning letter to the drugmaker—dated May 29 and publicly released this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback